The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
With standout ADC and t-cell engager response data across hard-to-treat cancers
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
